Tissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostat

ΔNp63/DGCR8-Dependent MicroRNAs Mediate Therapeutic Efficacy of HDAC Inhibitors in Cancer

(2016) Marco Napoli et al.   CANCER CELL

A genome scale RNAi screen identifies GLI1 as a novel gene regulating vorinostat sensitivity

(2016) K J Falkenberg et al.   CELL DEATH AND DIFFERENTIATION

Transglutaminase 2 has opposing roles in the regulation of cellular functions as well as cell growth and death

(2016) H Tatsukawa et al.   Cell Death & Disease

Oncogenic K-ras confers SAHA resistance by up-regulating HDAC6 and c-myc expression

(2016) Qun Wang et al.   Oncotarget

SAHA triggered MET activation contributes to SAHA tolerance in solid cancer cells

(2015) Ling Ding et al.   CANCER LETTERS

FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma

(2015) H.-Z. Lee et al.   CLINICAL CANCER RESEARCH

Panobinostat Approved for Multiple Myeloma

(2015)   Cancer Discovery

MAPK pathway activation leads to Bim loss and histone deacetylase inhibitor resistance: rationale to combine romidepsin with an MEK inhibitor

(2013) A. R. Chakraborty et al.   BLOOD

Loss of the proteins Bak and Bax prevents apoptosis mediated by histone deacetylase inhibitors

(2013) Caterina Ieranò et al.   CELL CYCLE

Romidepsin for peripheral T-cell lymphoma

(2013) Amit Khot et al.   Expert Review of Hematology

Tissue transglutaminase: a new target to reverse cancer drug resistance

(2011) Alfredo Budillon et al.   AMINO ACIDS

Histone Deacetylase Inhibitors: Emerging Mechanisms of Resistance

(2011) Robert W. Robey et al.   MOLECULAR PHARMACEUTICS

Role of checkpoint kinase 1 (Chk1) in the mechanisms of resistance to histone deacetylase inhibitors

(2011) J.-H. Lee et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Acetylation of EGF receptor contributes to tumor cell resistance to histone deacetylase inhibitors

(2010) Hui Song et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase

(2010) E Di Gennaro et al.   BRITISH JOURNAL OF CANCER

Modulation of thymidilate synthase and p53 expression by HDAC inhibitor vorinostat resulted in synergistic antitumor effect in combination with 5FU or Raltitrexed

(2010) Elena Di Gennaro et al.   CANCER BIOLOGY & THERAPY

TGM2 Is a Novel Marker for Prognosis and Therapeutic Target in Colorectal Cancer

(2009) Norikatsu Miyoshi et al.   ANNALS OF SURGICAL ONCOLOGY

HDACi – Targets beyond chromatin

(2009) Marc Buchwald et al.   CANCER LETTERS

Histone Deacetylase Inhibitors in Cancer Therapy

(2009) Andrew A. Lane et al.   JOURNAL OF CLINICAL ONCOLOGY

Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis

(2009) F. Bruzzese et al.   MOLECULAR CANCER THERAPEUTICS

Transglutaminase 2 suppresses apoptosis by modulating caspase 3 and NF-κB activity in hypoxic tumor cells

(2009) G -Y Jang et al.   ONCOGENE

In vivo evaluation of type 2 transglutaminase contribution to the metastasis formation in melanoma

(2008) G. Di Giacomo et al.   AMINO ACIDS

Protein–polyamine conjugates by transglutaminase 2 as potential markers for antineoplastic screening of natural compounds

(2008) A. Lentini et al.   AMINO ACIDS

Tissue transglutaminase protects epithelial ovarian cancer cells from cisplatin-induced apoptosis by promoting cell survival signaling

(2008) L. Cao et al.   CARCINOGENESIS

Identification of Chemical Inhibitors to Human Tissue Transglutaminase by Screening Existing Drug Libraries

(2008) Thung-S. Lai et al.   CHEMISTRY & BIOLOGY